Jump to content

Talk:Duvelisib

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Wowbagger2 (talk | contribs) at 14:46, 27 December 2017. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Patents

I haven't seen a table of patent info in other drug articles, so I'm wondering if it adds relevant info to the article here. It's an article about an experimental drug, so I can see the argument for including it because the topic is different than that of marketed drugs, but I'd like other opinions. Natureium (talk) 15:19, 19 January 2017 (UTC)[reply]

Very happy to see that gone. It is taken from pubchem which is not necessarily reliable for this subject of patents, and who ever added it to this article made some selection of patents listed in pubchem that is basically OR. Jytdog (talk) 17:35, 19 January 2017 (UTC)[reply]
I chopped out the table and left the one sentence explanation. Natureium (talk)

The long and twisty path to Verastem

Robert Forrester, CEO of Verastem, answered some questions about the way Duvelisib ended up at Verastem in the Nov 14, 2017 in the Q&A after his presentation at the Jefferies healthcare conference, and there is more to it than is explained in the wikipedia article. Some of it is hard to make out on the webcast, but it sounds extremely interesting. (Anyone can see the webcast, but this sort of presentation tends to disappear from the webcast after some small number of months.) 108.45.80.41 (talk) 08:47, 18 November 2017 (UTC)[reply]

This drug was considered as 'failed' by infinity, as NHL results in the duo study were not as planned. (There is a on almost emotional PR from Infinity on this). The CLL trial was ongoing, and the compound sold to Verastem, for little money. This year, the CLL trial had been found to be successful. Wowbagger2 (talk) 14:46, 27 December 2017 (UTC)[reply]